Skip to main content
. 2022 Jun 22;8:114–115. doi: 10.1016/j.jdin.2022.06.016

Table I.

ROR for terbinafine-LEE reports according to indication

Variables assessed FAERS ROR (CI) CVARO ROR (CI)
Terbinafine-LEE Reports
Non-Onychomycosis		 1.71 (1.07-2.72) 1.51 (0.37-6.09)
Terbinafine-LEE Reports
Nail Infections		 4.58 (3.84-5.46) 4.51 (2.64-7.68)
Isoniazid-LEE Reports 5.35 (5.06-5.67) 5.51 (5.00-6.07)

RORs are listed for terbinafine and onychomycosis and non-onychomycosis indications. In brackets are each ROR’s confidence intervals. FDA adverse event reporting system and Canada Vigilance Adverse Reaction Online RORs are listed in their respective columns.

CVARO, Canada Vigilance Adverse Reaction Online; FAERS, FDA Adverse Drug Event Reporting System; LEE, liver enzyme elevation; ROR, reporting odds ratio.